N@N

Q, BG, CEPH, RDY, MCCC, ELN Are Seasonally Ripe To Go Higher In The Next 5 Weeks

^{Published on 2009-11-25 07:47:37, Last Modified on 2010-12-22 17:36:57 - WOPRAI}
 

November 25, 2009 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Qwest Communications (NYSE: Q), Bunge Limited (NYSE: BG), Cephalon (NASDAQ: CEPH), Dr. Reddys Laboratories (NYSE: RDY), Mediacom (NASDAQ: MCCC) and Elan Corp (NYSE: ELN) and each have a high seasonal probability to go higher in the next 5 weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go higher:

Symbol Company Expected Return Odds Trading Days

Q Qwest Communications 14.21% 100% (12 of 12) t+26

BG Bunge Limited 14.17% 100% (8 of 8) t+31

CEPH Cephalon, Inc. 14.12% 78% (14 of 18) t+28

RDY Dr. Reddy's Lab 13.36% 100% (8 of 8) t+26

MCCC Mediacom Communications 13.20% 78% (7 of 9) t+22

ELN Elan Corporation plc 13.12% 68% (17 of 25) t+31

Qwest Communications International Inc. (NYSE: Q) provides data, Internet, video, and voice services in the United States and internationally. The company offers its products and services using telecommunications network, which consists of voice and data switches, copper cables, fiber optic broadband cables, and other equipment to mass markets, business, and wholesale customers. It provides various data and Internet services, including private line, multi-protocol label switching, broadband, and data integration services, as well as Web hosting and related services comprising provision space, power, bandwidth, and managed services in data centers; and server and application management, back-up, disaster recovery, and Web design services. Its data and Internet services also consist of traditional wide area network products, such as ATM, frame relay, dedicated Internet access, and virtual private network; integrated services digital network; and Internet dial-up access. The companya�s voice services include local voice services comprising basic local exchange and switching services; local voice exchange services, such as caller ID, call waiting, call return, 3-way calling, call forwarding, and voice mail; long-distance voice services consisting of domestic and international long-distance services, and toll free services; and wireless products and services. Qwest Communications Internationalas data, Internet, and video services comprise Internet, Internet-based services, and digital television. The company also engages in lease and sublease of real estate properties, such as space in office buildings, warehouses, and other properties. It sells its products and services through its sales and call centers, Web site, telemarketing, retail stores, and kiosks, as well as relationships and arrangements with third-party sales agents. The company has a strategic partnership with DIRECTV Group Inc. Qwest Communications International was founded in 1983 and is based in Denver, Colorado.

Bunge Limited (NYSE: BG) engages in the agriculture and food business worldwide. It operates in three divisions: Agribusiness, Fertilizer, and Food Products. The Agribusiness division purchases, stores, transports, processes, and sells agricultural commodities, including grains and oilseeds, such as soybeans, rapeseed or canola, sunflower seeds, wheat, and corn; and commodity products. It sells its products to animal feed manufacturers, wheat and corn millers, and oilseed processors; livestock, poultry, and aquaculture producers; and edible oil processing companies. The Fertilizer division produces and supplies fertilizers to farmers. It engages in nutrients and retail operations, including mining and processing phosphate ore; and the production of intermediate phosphate-based products for sale to fertilizer blenders. This divisiona�s products include phosphate rock, sulfuric acid, phosphoric acid, single super phosphate, and dicalcium phosphate, and phosphate-based animal feed ingredients. It also produces, distributes, and sells blended NPK formulas and other fertilizer products directly to retailers, processing and trading companies, and farmers. The Food Products division offers edible oil products and milling products for food processors, foodservice companies, and retail outlets. Its edible oil products include packaged and bulk oils, shortenings, margarines, mayonnaise, and other products derived from the vegetable oil refining process; and milling products comprise various wheat flours and bakery mixes, and corn-based products derived from the corn dry milling process consisting primarily of dry milled corn meal, flours, grits, soy-fortified corn meal, corn-soy blend, corn oil, and corn feed products. Bunge Limited was founded in 1818 and is headquartered in White Plains, New York.

Cephalon, Inc. (NASDAQ: CEPH), a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients. The companya�s pain therapeutics portfolio comprises AMRIX for the relief of muscle spasm associated with acute painful musculoskeletal conditions; and FENTORA, EFFENTORA, ACTIQ, and generic OTFC products, which focus on treating breakthrough cancer pain in opioid-tolerant patients. Its products for oncology consist of TREANDA, a bi-functional hybrid cytotoxic; TRISENOX, an intravenous arsenic-based targeted therapy; CEP-701, an oral small molecule tyrosine kinase inhibitor; MYOCET, a cardio-protective chemotherapy agent to treat metastatic breast cancer; TARGRETIN for the treatment of cutaneous T-cell lymphoma; and ABELCET, an anti-fungal product for cancer patients. The company provides its products principally to wholesale drug distributors. It has collaboration agreements with Euroscreen s.a.; Ligand Pharmaceuticals Incorporated; Psychogenics Inc.; and AMBIT Biosciences Inc, as well as a research agreement with Celator Pharmaceuticals Inc. Cephalon, Inc. markets its products primarily in the United States, Europe, the Middle East, and Africa. The company was founded in 1987 and is headquartered in Frazer, Pennsylvania.

Dr. Reddys Laboratories Limited (NYSE: RDY), together with its subsidiaries, operates as a pharmaceutical company. It produces finished dosage forms, active pharmaceutical ingredients and intermediates, and biotechnology products. The company also conducts research in the areas of cancer, diabetes, cardiovascular, inflammation, and bacterial infection. In addition, it involves in the contract manufacture generic prescription and over-the-counter products for branded and generic companies in the United States. The company primarily focuses on therapeutic categories of cardiovascular, diabetes management, gastro-intestinal, and pain management. It markets its products in India, the United States, Europe, and the Russian Federation. The company has a co-development and commercialization agreement with Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec International for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; and an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease. It also has an agreement with 7TM Pharma for drug discovery collaboration on selected drug targets; and an agreement with GlaxoSmithKline plc to develop and market pharmaceuticals for the treatment of cardiovascular disease, diabetes, oncology, gastroenterology, and pain management. Dr. Reddya�s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Mediacom Communications Corporation (NASDAQ: MCCC) develops cable systems to provide entertainment, information, and telecommunications services in the United States. It offers an array of products and services, including video services, such as broadcast basic services, family basic services, digital services, pay-per-view services, video-on-demand services, high-definition television services, and digital video recorders; and high-speed data (HSD) products that offer cable modem-based services, such as interactive portal, multiple email addresses, personal Web space, and local community content services. The company also provides voice over Internet protocol phone services that provide local, regional, and long-distance calling within the United States, Puerto Rico, the U.S. Virgin Islands, and Canada, as well as offer calling features, such as caller ID with name and number, call waiting, three-way calling, emergency dialing, directory assistance and voice mail, and international calling services; and contact centers and network management and field operations services. In addition, it offers various advanced data services for the commercial markets, such as various packages of HSD services, which include business email, Web space storage, and IP address options for small and medium-sized businesses; customized Internet access and data transport solutions for the healthcare, financial services, and education markets; and point-to-point circuits to carry voice and HSD traffic for wireless communication providers. As of December 31, 2008, its cable systems passed approximately 2.85 million homes and served 1.32 million basic subscribers. The company provided digital video services to 643,000 customers; HSD services to 737,000 customers; and telephone services to 248,000 customers. Mediacom Communications Corporation was founded in 1995 and is based in Middletown, New York.

Elan Corporation, plc (NYSE: ELN) operates as a neuroscience-based biotechnology company primarily in Ireland and the United States. It operates in two segments, Biopharmaceuticals and Elan Drug Technologies (EDT). The Biopharmaceuticals segment engages in the research, development, and commercial activities primarily in Alzheimera�s disease, Parkinsona�s disease, multiple sclerosis, Crohna�s disease, severe chronic pain, and infectious diseases. It offers Tysabri, an alpha 4 integrin antagonist for the treatment of relapsing forms of multiple sclerosis; Prialt for the management of severe chronic pain; Maxipime, an injectable cephalosporin antibiotic to treat serious and/or life-threatening infections; and Azactam, an injectable antibiotic to treat pneumonia, post-surgical infections, and septicemia. This segment, through collaboration with Biogen Idec, Inc., develops and markets Tysabri as a treatment for Crohna�s disease. It also develops ELND005, a small molecule therapeutic that acts by breaking down and preventing the aggregation of beta amlyoid fibrils in collaboration with Transition Therapeutics, Inc. In addition, Biopharmaceuticals segment, through collaboration with Wyeth, develops beta amyloid immunotherapies, including AAB-001 and ACC-001, which are in various stages of development for the treatment of Alzheimera�s disease. The EDT segment engages in the development and manufacture of drug optimization technologies. It also offers a range of services, which include formulation development, clinical trial management, analytical development, clinical trial material manufacturing, scale-up, product registration support, and supply chain management for client products. Elan Corporation sells its products primarily to drug wholesalers worldwide. It has a development agreement with Circ Pharma Limited to develop a chronotherapeutic formulation of Tramadol for the treatment of severe pain. The company was founded in 1969 and is headquartered in Dublin, Ireland.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641